Intravenous  	Intravenous  	 JJ	B-NP
temsirolimus  	temsirolimus  	 NN	I-NP
in  	in  	 IN	O
cancer  	cancer  	 NN	B-NP
patients 	patients 	 NNS	I-NP
:  	:  	 :	O
clinical  	clinical  	 JJ	B-NP
pharmacology  	pharmacology  	 NN	I-NP
and  	and  	 CC	O
dosing  	dosing  	 JJ	O
considerations  	considerations  	 NNS	B-NP
Temsirolimus 	Temsirolimus 	 NNP	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
highly  	highly  	 RB	O
specific  	specific  	 JJ	O
inhibitor  	inhibitor  	 NN	O
of  	of  	 IN	O
mammalian  	mammalian  	 JJ	B-NP
target  	target  	 NN	I-NP
of  	of  	 IN	I-NP
rapamycin  	rapamycin  	 NNS	I-NP
( 	( 	 -LRB-	O
mTOR 	mTOR 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
is  	is  	 VBZ	O
a  	a  	 DT	O
novel  	novel  	 NN	O
anticancer  	anticancer  	 VBZ	O
targeted  	targeted  	 VBN	B-NP
therapy  	therapy  	 NN	I-NP
with  	with  	 IN	O
a  	a  	 DT	O
new  	new  	 JJ	O
mechanism  	mechanism  	 NN	O
of  	of  	 IN	O
action 	action 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
prototype  	prototype  	 JJ	O
mTOR  	mTOR  	 JJ	B-NP
inhibitor 	inhibitor 	 NN	I-NP
,  	,  	 ,	O
oral  	oral  	 JJ	B-NP
rapamycin 	rapamycin 	 NN	I-NP
,  	,  	 ,	O
is  	is  	 VBZ	O
poorly  	poorly  	 RB	O
soluble  	soluble  	 JJ	O
and  	and  	 CC	O
undergoes  	undergoes  	 JJ	B-NP
extensive  	extensive  	 JJ	I-NP
first-pass  	first-pass  	 JJ	I-NP
metabolism 	metabolism 	 NN	I-NP
,  	,  	 ,	O
leading  	leading  	 VBG	O
to  	to  	 TO	O
low  	low  	 JJ	O
and  	and  	 CC	O
potentially  	potentially  	 RB	O
variable  	variable  	 JJ	O
absorption  	absorption  	 NN	O
and  	and  	 CC	O
exposure 	exposure 	 NN	O
.  	.  	 .	O
For  	For  	 IN	O
some  	some  	 DT	O
tumors 	tumors 	 NNS	O
,  	,  	 ,	O
maximizing  	maximizing  	 VBG	O
the  	the  	 DT	O
bioavailability  	bioavailability  	 NN	B-NP
and  	and  	 CC	O
dose  	dose  	 JJ	O
intensity  	intensity  	 NN	O
via  	via  	 IN	O
intravenous  	intravenous  	 NNS	B-NP
( 	( 	 -LRB-	O
IV 	IV 	 NNP	B-NP
)  	)  	 -RRB-	O
administration  	administration  	 NN	B-NP
may  	may  	 MD	O
provide  	provide  	 VB	O
optimal  	optimal  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
benefit 	benefit 	 NN	I-NP
.  	.  	 .	O
Temsirolimus  	Temsirolimus  	 NNP	B-NP
is  	is  	 VBZ	O
an  	an  	 DT	O
ester  	ester  	 JJ	O
analog  	analog  	 NN	O
of  	of  	 IN	O
rapamycin  	rapamycin  	 NNS	B-NP
that  	that  	 WDT	O
retains  	retains  	 VBZ	O
its  	its  	 PRP$	O
potent  	potent  	 JJ	O
intrinsic  	intrinsic  	 JJ	B-NP
mTOR  	mTOR  	 JJ	I-NP
inhibitory  	inhibitory  	 JJ	I-NP
activity  	activity  	 NN	I-NP
while  	while  	 IN	O
exhibiting  	exhibiting  	 VBG	O
better  	better  	 JJR	O
solubility  	solubility  	 NN	B-NP
for  	for  	 IN	O
IV  	IV  	 NNP	O
formulation 	formulation 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
advanced  	advanced  	 JJ	O
renal  	renal  	 JJ	B-NP
cell  	cell  	 NN	I-NP
carcinoma 	carcinoma 	 NN	I-NP
,  	,  	 ,	O
temsirolimus  	temsirolimus  	 NN	B-NP
is  	is  	 VBZ	O
administered  	administered  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
30-  	30-  	 NN	O
to  	to  	 TO	O
60-minute  	60-minute  	 NNP	O
IV  	IV  	 NNP	O
infusion  	infusion  	 NN	O
once  	once  	 RB	O
weekly  	weekly  	 JJ	O
at  	at  	 IN	O
a  	a  	 DT	O
flat  	flat  	 JJ	O
dose  	dose  	 NN	O
of  	of  	 IN	O
25  	25  	 CD	O
mg 	mg 	 NNS	B-NP
.  	.  	 .	O
This  	This  	 DT	O
dosage  	dosage  	 JJ	B-NP
results  	results  	 NNS	I-NP
in  	in  	 IN	O
high  	high  	 JJ	O
peak  	peak  	 NN	B-NP
temsirolimus  	temsirolimus  	 NN	I-NP
concentrations  	concentrations  	 NNS	I-NP
and  	and  	 CC	O
limited  	limited  	 JJ	O
immunosuppressive  	immunosuppressive  	 JJ	B-NP
activity 	activity 	 NN	I-NP
.  	.  	 .	O
Because  	Because  	 IN	O
temsirolimus  	temsirolimus  	 NN	B-NP
is  	is  	 VBZ	O
active  	active  	 JJ	O
and  	and  	 CC	O
well  	well  	 RB	O
tolerated 	tolerated 	 JJ	O
,  	,  	 ,	O
different  	different  	 JJ	O
dosages  	dosages  	 NN	O
and  	and  	 CC	O
schedules  	schedules  	 NNS	O
are  	are  	 VBP	O
being  	being  	 VBG	B-NP
explored  	explored  	 NN	I-NP
for  	for  	 IN	O
other  	other  	 JJ	O
solid  	solid  	 JJ	O
and  	and  	 CC	O
hematologic  	hematologic  	 JJ	B-NP
malignancies 	malignancies 	 NN	I-NP
,  	,  	 ,	O
including  	including  	 VBG	B-NP
mantle  	mantle  	 JJ	I-NP
cell  	cell  	 NN	I-NP
lymphoma 	lymphoma 	 NN	I-NP
.  	.  	 .	O
Temsirolimus  	Temsirolimus  	 NNP	B-NP
exhibits  	exhibits  	 VBZ	O
a  	a  	 DT	O
high  	high  	 JJ	O
volume  	volume  	 NN	O
of  	of  	 IN	O
distribution  	distribution  	 NN	B-NP
that 	that 	 IN	O
,  	,  	 ,	O
together  	together  	 RB	O
with  	with  	 IN	O
IV  	IV  	 NNP	O
administration 	administration 	 NN	B-NP
,  	,  	 ,	O
leads  	leads  	 VBZ	O
to  	to  	 TO	O
extensive  	extensive  	 JJ	B-NP
distribution  	distribution  	 NN	I-NP
into  	into  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
tissues 	tissues 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
significant  	significant  	 JJ	O
and  	and  	 CC	O
protracted  	protracted  	 JJ	O
exposures  	exposures  	 NNS	O
are  	are  	 VBP	O
attained  	attained  	 VBN	O
with  	with  	 IN	O
sirolimus  	sirolimus  	 NNS	B-NP
( 	( 	 -LRB-	O
rapamycin 	rapamycin 	 LS	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
the  	the  	 DT	O
major  	major  	 JJ	O
equipotent  	equipotent  	 JJ	B-NP
metabolite  	metabolite  	 NN	I-NP
of  	of  	 IN	I-NP
temsirolimus 	temsirolimus 	 NN	I-NP
.  	.  	 .	O
Whereas  	Whereas  	 IN	O
temsirolimus  	temsirolimus  	 NN	B-NP
and  	and  	 CC	O
sirolimus  	sirolimus  	 NNS	B-NP
are  	are  	 VBP	O
both  	both  	 DT	O
metabolized  	metabolized  	 NN	O
by  	by  	 IN	O
cytochrome  	cytochrome  	 CD	B-NP
P450  	P450  	 CD	I-NP
( 	( 	 -LRB-	O
CYP 	CYP 	 NNP	B-NP
)  	)  	 -RRB-	O
3A4 	3A4 	 NNP	B-NP
,  	,  	 ,	O
drug  	drug  	 NN	B-NP
interaction  	interaction  	 NN	I-NP
studies  	studies  	 NNS	I-NP
with  	with  	 IN	O
agents  	agents  	 NNS	O
that  	that  	 IN	O
induce  	induce  	 NN	O
or  	or  	 CC	O
inhibit  	inhibit  	 VB	O
CYP3A4  	CYP3A4  	 CD	O
activity  	activity  	 NN	O
indicate  	indicate  	 VBP	O
that  	that  	 DT	O
exposure  	exposure  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
sirolimus  	sirolimus  	 JJ	B-NP
metabolite  	metabolite  	 NN	I-NP
is  	is  	 VBZ	O
somewhat  	somewhat  	 RB	O
sensitive  	sensitive  	 JJ	O
to  	to  	 TO	O
pharmacokinetic  	pharmacokinetic  	 VB	B-NP
( 	( 	 -LRB-	O
PK 	PK 	 NNP	B-NP
)  	)  	 -RRB-	O
drug  	drug  	 NN	B-NP
interaction 	interaction 	 NN	I-NP
.  	.  	 .	O
Therefore 	Therefore 	 RB	O
,  	,  	 ,	O
temsirolimus  	temsirolimus  	 JJ	B-NP
dose  	dose  	 NN	I-NP
adjustments  	adjustments  	 NNS	I-NP
are  	are  	 VBP	O
warranted  	warranted  	 VBN	O
if  	if  	 IN	O
coadministration  	coadministration  	 JJ	O
cannot  	cannot  	 NNS	O
be  	be  	 VB	O
avoided 	avoided 	 VBN	O
.  	.  	 .	O
Despite  	Despite  	 IN	O
its  	its  	 PRP$	O
complexity 	complexity 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
PK  	PK  	 NNP	B-NP
profile  	profile  	 NN	I-NP
of  	of  	 IN	O
IV  	IV  	 NNP	O
temsirolimus  	temsirolimus  	 NN	B-NP
is  	is  	 VBZ	O
well  	well  	 RB	O
characterized  	characterized  	 VBN	O
in  	in  	 IN	O
cancer  	cancer  	 NN	B-NP
patients  	patients  	 NNS	I-NP
and  	and  	 CC	O
provides  	provides  	 VBZ	O
a  	a  	 DT	O
strong  	strong  	 JJ	O
basis  	basis  	 NN	O
for  	for  	 IN	O
its  	its  	 PRP$	O
future  	future  	 JJ	O
study  	study  	 NN	O
as  	as  	 IN	O
a  	a  	 DT	O
monotherapy  	monotherapy  	 NN	B-NP
or  	or  	 CC	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
other  	other  	 JJ	O
anticancer  	anticancer  	 JJ	B-NP
agents 	agents 	 NNS	I-NP
.  	.  	 .	O
